IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
ApexOnco Front Page
Recent articles
Daraxonrasib scores a plenary session late-breaker.
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
The drug adds a new use to its US label, but Takeda’s 2017 Ariad acquisition still looks expensive.
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.
AstraZeneca's quiet, cautious work is followed by a $2bn takeover.
Carvykti sailed through Friday’s adcom, but Abecma got a much rougher ride.
Three recently added trials take Merck & Co’s tally of phase 3 sacituzumab tirumotecan studies to six.